Autologous MAGE-A3/A6-specific TCR gene-engineered lymphocytes KITE-718

{
  "id": "MLC-T-ONC-011683",
  "term": "Autologous MAGE-A3/A6-specific TCR gene-engineered lymphocytes KITE-718",
  "field": "Oncology and biomedicine",
  "definition": "Human autologous T lymphocytes genetically modified to express a T-cell receptor (TCR) that specifically targets human melanoma-associated antigen A3 (MAGE-A3) and MAGE-A6 (MAGEA3/A6; MAGE-A3/A6), with potential antineoplastic activity. Peripheral blood mononuclear cells (PBMCs) are isolated from a patient, transduced with a gene expressing a TCR specific for the MAGE-A3/A6 antigens, expanded ex vivo, and reintroduced into the patient. Then, the autologous MAGE-A3/A6-specific TCR gene engineered lymphocytes KITE-718 target and bind to tumor cells expressing the MAGE-A3 and/or MAGE-A6 antigens. This halts the growth of and kills MAGE-A3/A6-expressing cancer cells. The tumor-associated antigens MAGE-A3 and MAGE-A6 are overexpressed on a variety of tumor cell types.",
  "synonyms": [
    "MAGEA3/A6-targeted TCR-transduced T cells KITE-718",
    "MAGE-A3/A6 T cell receptor engineered T cells",
    "MAGE-A3/A6 TCR engineered T lymphocytes",
    "TCR-transduced autologous T cells KITE-718",
    "MAGE-A3/A6 T cell receptor engineered T cells KITE-718",
    "autologous anti-MAGE-A3/A6 TCR-transduced T cells KITE-718"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-mage-a3-a6-specific-tcr-gene-engineered-lymphocytes-kite-718/"
}